Our results suggest that among individuals who are enriched for AD risk, APOE genotype modulates the association between SCD and brain alterations, possibly reflecting a preclinical disease process that precedes overt clinically significant cognitive dysfunction. The gene discussed is APOE; the disease is Alzheimer disease.